WO2009103218A8 - Dérivés d'hydrazine carboxamide d'éthylidène, processus de préparation et utilisation pharmaceutique de ceux-ci - Google Patents

Dérivés d'hydrazine carboxamide d'éthylidène, processus de préparation et utilisation pharmaceutique de ceux-ci Download PDF

Info

Publication number
WO2009103218A8
WO2009103218A8 PCT/CN2009/000136 CN2009000136W WO2009103218A8 WO 2009103218 A8 WO2009103218 A8 WO 2009103218A8 CN 2009000136 W CN2009000136 W CN 2009000136W WO 2009103218 A8 WO2009103218 A8 WO 2009103218A8
Authority
WO
WIPO (PCT)
Prior art keywords
preparation process
pharmaceutical use
carboxamide derivatives
ethylidene
hydrazine carboxamide
Prior art date
Application number
PCT/CN2009/000136
Other languages
English (en)
Chinese (zh)
Other versions
WO2009103218A1 (fr
Inventor
邓炳初
吕贺军
陈一千
宋鹏
王胜蓝
Original Assignee
上海恒瑞医药有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 上海恒瑞医药有限公司 filed Critical 上海恒瑞医药有限公司
Priority to CN2009800002470A priority Critical patent/CN101679242B/zh
Publication of WO2009103218A1 publication Critical patent/WO2009103218A1/fr
Publication of WO2009103218A8 publication Critical patent/WO2009103218A8/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • C07D207/2632-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/40Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of thiourea or isothiourea groups further bound to other hetero atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18One oxygen or sulfur atom
    • C07D231/20One oxygen atom attached in position 3 or 5
    • C07D231/22One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04Five-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention concerne des dérivés d'hydrazide carboxamide d'éthylidène représentés par la formule (I) ou des sels, un hydrate ou un solvate pharmaceutiquement acceptables de ceux-ci, des procédés de préparation de ces dérivés, des compositions pharmaceutiques les contenants et leur utilisation comme agent thérapeutique, en particulier comme mimétiques de thrombopoïétine (TPO) et leur utilisation comme agonistes du récepteur de thrombopoïétine. Les définitions des substituants dans la formule (I) sont telles que présentées dans la description.
PCT/CN2009/000136 2008-02-21 2009-02-06 Dérivés d'hydrazine carboxamide d'éthylidène, processus de préparation et utilisation pharmaceutique de ceux-ci WO2009103218A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2009800002470A CN101679242B (zh) 2008-02-21 2009-02-06 亚乙基肼酰胺类衍生物、其制备方法及其在医药上的应用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN200810006179.6 2008-02-21
CNA2008100061796A CN101514179A (zh) 2008-02-21 2008-02-21 吲哚酮亚乙基肼羰基化合物、其制备方法及其在医药上的应用

Publications (2)

Publication Number Publication Date
WO2009103218A1 WO2009103218A1 (fr) 2009-08-27
WO2009103218A8 true WO2009103218A8 (fr) 2009-12-03

Family

ID=40985060

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2009/000136 WO2009103218A1 (fr) 2008-02-21 2009-02-06 Dérivés d'hydrazine carboxamide d'éthylidène, processus de préparation et utilisation pharmaceutique de ceux-ci

Country Status (2)

Country Link
CN (2) CN101514179A (fr)
WO (1) WO2009103218A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2492262B1 (fr) 2009-10-23 2016-04-20 Nissan Chemical Industries, Ltd. Composés hétérocycles fusionnés et activateur du récepteur de la thrombopoïétine
CN109293551A (zh) * 2011-11-14 2019-02-01 利亘制药公司 与粒细胞集落刺激因子受体相关的方法和组合物
WO2014150252A1 (fr) * 2013-03-15 2014-09-25 Ligand Pharmaceuticals Incorporated Méthodes de traitement associées au récepteur du facteur de stimulation des colonies de granulocytes
CN104628647A (zh) * 2013-11-12 2015-05-20 上海医药工业研究院 3-甲基-1-(3,4-二甲基苯基)-2-吡唑啉-5-酮的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005509616A (ja) * 2001-10-16 2005-04-14 センジェント・セラピューティクス・インク チロシンホスファターゼに対する有機硫黄阻害剤
TWI324593B (en) * 2002-10-09 2010-05-11 Nissan Chemical Ind Ltd Pyrazolone compounds and thrombopoietin receptor activator
EP1841749A1 (fr) * 2004-09-02 2007-10-10 Metabasis Therapeutics, Inc. Derives d'inhibiteurs de thiazole et de thiadiazoles de tyrosine phosphatases
TWI399368B (zh) * 2004-12-14 2013-06-21 Nissan Chemical Ind Ltd Amide compounds and thrombopoietin receptor activators
WO2007062078A2 (fr) * 2005-11-23 2007-05-31 Ligand Pharmaceuticals Inc. Composes modulant l'activite thrombopoietine et procedes correspondants

Also Published As

Publication number Publication date
CN101514179A (zh) 2009-08-26
WO2009103218A1 (fr) 2009-08-27
CN101679242A (zh) 2010-03-24
CN101679242B (zh) 2013-07-10

Similar Documents

Publication Publication Date Title
MX2010007553A (es) Derivados de azopirazolona biciclo-sustituidos, procedimiento de preparacion y uso farmaceutico de los mismos.
MX2009006474A (es) Derivados de benzamida como agonistas del receptor ep4.
MX2011012639A (es) Sales de derivados de pirazolon azo sustituidos con biciclo, metodo de preparacion y uso de los mismos.
WO2007065808A3 (fr) Agonistes du récepteur du neuropeptide-2
WO2008048981A3 (fr) Antagonistes d'indole du récepteur p2y1 utiles dans le traitement d'états thrombotiques
WO2008039489A3 (fr) Dérivés de quinazolinone substitués en 5', compositions contenant ces dérivés et procédés d'utilisation
ME01488B (me) Derivati oksadiazola i njihovo korišćenje kao potencijatora metabotropnih glutamatnih receptora-842
WO2008010921A3 (fr) Modulateurs de propriétés pharmacocinétiques d'agents thérapeutiques
MY146645A (en) Purine derivatives for use as adenosin a2a receptor agonists
MY149622A (en) Pyrazoles as 11-beta-hsd-1
WO2008006795A3 (fr) Composés d'indole
TW200637874A (en) Peptides with neuropeptide-2 receptor (Y2R) agonist activity
MX2010003155A (es) Derivados de ciclopropil aril amida y uso de los mismos.
TW200833693A (en) Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
WO2010052144A3 (fr) Agonistes du récepteur 2 de neuropeptide (y-2r) et leurs utilisations
WO2006077025A3 (fr) Morpholines en tant qu'agonistes de 5ht2c
RS20090036A (en) Pyrazole derivatives as cytochrom p450 inhibitors
WO2008135791A8 (fr) Imidazoquinolines dotées de propriétés immuno-modulatrices
TW200643013A (en) Pyrazoles
TW200738729A (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
WO2007120575A3 (fr) Agonistes du récepteur de la niacine, compositions contenant de tels composés et méthodes de traitement
TNSN08544A1 (en) Purine derivatives as a2a agonists
WO2008035359A3 (fr) Acide oxyminophénoxyalcanoïque et dérivés de l'acide phenylalcanoïque
WO2011045232A3 (fr) Agonistes du récepteur du neuropeptide-2 (y-2r)
DE602006018713D1 (de) Als agonisten für den nikotinischen acetylcholinrezeptor geeignete azabicycloalkanderivate

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980000247.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09713556

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09713556

Country of ref document: EP

Kind code of ref document: A1